Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 13
Submit an article Journal homepage
390
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)

Byeong-Bae ParkDepartment of Internal Medicine, Division of Hematology/Oncology, Hanyang University College of Medicine, Seoul, Korea; ORCID Iconhttp://orcid.org/0000-0001-8794-2508
ORCID Icon,
Won Seog KimDepartment of Medicine, Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan, University School of Medicine, Seoul, Korea; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-5400-0466
ORCID Icon,
Cheolwon SuhDepartment of Oncology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea; ORCID Iconhttp://orcid.org/0000-0002-9178-4431
ORCID Icon,
Jung Yong HongDepartment of Oncology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea; ORCID Iconhttp://orcid.org/0000-0003-1363-9332
ORCID Icon,
Deok-Hwan YangDepartment of Hemato-Oncology, Chonnam National University Hwasun Hospital, Gwangju, Korea; ORCID Iconhttp://orcid.org/0000-0003-2830-9889
ORCID Icon,
Won Sik LeeDepartment of Internal Medicine, Division of Hematology, Inje University Busan Paik Hospital, Busan, Korea; ORCID Iconhttp://orcid.org/0000-0002-7956-468X
ORCID Icon,
Young Rok DoDepartment of Medicine, Division of Hematology-Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea; ORCID Iconhttp://orcid.org/0000-0003-1631-1359
ORCID Icon,
Young Il KohDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea; ORCID Iconhttp://orcid.org/0000-0002-5100-9473
ORCID Icon,
Jong-Ho WonDepartment of Internal Medicine, Soon Chun Hyang University, Seoul, South Korea; ORCID Iconhttp://orcid.org/0000-0001-6176-1442
ORCID Icon,
Min Kyoung KimDepartment of Medicine, Yeungnam University College of Medicine, Daegu, Korea; ORCID Iconhttp://orcid.org/0000-0003-0291-8512
ORCID Icon,
Jae-Cheol JoDepartment of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea; ORCID Iconhttp://orcid.org/0000-0001-6014-7977
ORCID Icon,
Shin Young HyunDepartment of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea; ORCID Iconhttp://orcid.org/0000-0002-8137-8675
ORCID Icon,
Jeong-A KimDepartment of Internal Medicine, Division of Hematology, St. Vincent’s Hospital, Catholic University of Korea College of Medicine, Suwon, Korea; ORCID Iconhttp://orcid.org/0000-0002-1993-3316
ORCID Icon,
Young Ha OhDepartment of Pathology, Hanyang University College of Medicine, Seoul, Korea; ORCID Iconhttp://orcid.org/0000-0001-8750-9843
ORCID Icon &
Seung-Sook LeeDepartment of Pathology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, KoreaORCID Iconhttp://orcid.org/0000-0001-6714-5851
ORCID Icon show all
Pages 3251-3257 | Received 13 Jan 2019, Accepted 16 May 2019, Published online: 06 Jun 2019

References

  • El-Asmar J, Reljic T, Ayala E, et al. Efficacy of high-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphomas as front-line consolidation or in the relapsed/refractory setting: a systematic review/meta-analysis. Biol Blood Marrow Transplant. 2016;22:802–814.
  • Skamene T, Crump M, Savage KJ, et al. Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study. Leuk Lymphoma. 2017;58:2319–2327.
  • Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857–877.
  • Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–1976.
  • Rummel MJ, Gregory SA. Bendamustine’s emerging role in the management of lymphoid malignancies. Semin Hematol. 2011;48(1):S24–S36.
  • Derenzini E, Zinzani PL, Cheson BD. Bendamustine: role and evidence in lymphoma therapy, an overview. Leuk Lymphoma. 2014;55:1471–1478.
  • Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013;31:104–110.
  • Zaja F, Baldini L, Ferreri AJ, et al. Bendamustine salvage therapy for T cell neoplasms. Ann Hematol. 2013;92:1249–1254.
  • Koster W, Stamatis G, Heider A, et al. Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC). Clin Drug Investig. 2004;24:611–618.
  • Koster W, Heider A, Niederle N, et al. Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J Thorac Oncol. 2007;2:312–316.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
  • Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116:106–114.
  • Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204–210.
  • Dennie TW, Kolesar JM. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clin Ther. 2009;31:2290–2311.
  • Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:3383–3389.
  • Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4473–4479.
  • Reboursiere E, Le Bras F, Herbaux C, et al. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: a French retrospective multicenter study. Oncotarget. 2016;7:85573–85583.
  • Coiffier B, Federico M, Caballero D, et al. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treat Rev. 2014;40:1080–1088.
  • Park BB, Kim WS, Suh C, et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol. 2015;94:1845–1851.
  • O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182–1189.
  • Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol 2014;7:11.
  • O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33:2492–2499.
  • Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123:3095–3100.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.